Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU
The experimentally established mechanism targets of Tobramycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | GJB2 | P29033 | 5/20 | 0.51 |
| ▸ | GJA1 | P17302 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tobramycin SCHEMBL28251261 | 0.81 | ALOX15 (0.84) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL1178021 | 0.80 | ALOX15 (0.87) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL19678587 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL15263385 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL17145817 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL3658310 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL12930900 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL22364334 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL20953776 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 | |
| Tobramycin SCHEMBL17680145 | 0.79 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAAGJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1273917-B1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-05-07 | — | — | EP | disclosed |
| US-6664043-B2 | Detectable chemiluminescent acridinium ester label, comprising an acridinium ester with a hydrophilic modifier | BAYER CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1273917-A2 | Acridinium ester labels having hydrophilic modifiers | Bayer Corporation (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0410645-A2 | Automated analytical apparatus and method | TECHNICON INSTRUMENTS CORPORATION (US) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SRM, SMS, ACR | ALOX15 4407/4885HPSE 275/4885CYP3A4 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.